Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

Inclusion Criteria:

- Age ≥ 18 years

- Karnofsky performance status (KPS) ≥ 70

- Histologically confirmed malignancy with the presence of one to four intraparenchymal
brain metastases

- Each patient must sign a study-specific Informed Consent form

Exclusion Criteria:

- Previous cranial radiation

- Complete resection of all known brain metastases

- Known leptomeningeal metastases

- Known liver metastases

- Clinical or radiologic evidence of progression (other than study lesion[s) within 1
month prior to enrollment

- Patients with metastases within 10 mm of the optic apparatus

- Patients with metastases in the brainstem, midbrain, pons, or medulla

- Planned chemotherapy during WBRT and/or SRS

- Uncontrolled hypertension

- Women who are pregnant or lactating

and Laboratory values as follows:

- LDH > 1.3 x upper limit of normal (ULN)

- ANC < 1500/mm3

- Platelets < 50,000/mm3

- Creatinine > 2.0 mg/dL

- AST or ALT > 3 x ULN

- Total bilirubin > 2 x ULN